Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

81. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton G K, Tanajewski L, Turner D, Price A CRD summary RCTs directly comparing intravenous magnesium sulphate with sotalol were not identified, but the authors did conclude that intravenous magnesium is effective in preventing atrial fibrillation in patients undergoing coronary artery bypass graft when compared to controls. This was a well conducted piece of research, which considered limitations with the included studies. The authors' conclusions are likely to be reliable. Authors

DARE.2008

82. Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension

Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Drug Approval Package: Nexium (esomeprazole magnesium) NDA #022101 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Company: AstraZeneca LP Application No.: 022101 Approval Date: 2/27/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

FDA - Drug Approval Package2008

83. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.

A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. 18753646 2008 08 28 2008 09 03 2016 12 15 1533-4406 359 9 2008 Aug 28 The New England journal of medicine N. Engl. J. Med. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. 895-905 10.1056/NEJMoa0801187 Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy. In this multicenter, placebo-controlled (...) , double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age. A total of 2241 women underwent randomization. The baseline characteristics

NEJM2008 Full Text: Link to full Text with Trip Pro

84. Magnesium sulfate for persistent pulmonary hypertension of the newborn.

Magnesium sulfate for persistent pulmonary hypertension of the newborn. BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) occurs in approximately 1.9 per 1000 newborns and may be more frequent in developing countries. There is strong evidence for the use of inhaled nitric oxide (iNO) and extra corporeal membrane oxygenation (ECMO) in the treatment of PPHN. However, many developing countries do not have access or the technical expertise required for these expensive therapies (...) . Magnesium sulfate is a potent vasodilator and hence has the potential to reduce the high pulmonary arterial pressures associated with PPHN. If magnesium sulfate were found to be effective in the treatment of PPHN, this could be a cost effective and potentially life-saving therapy. OBJECTIVES: To evaluate the use of magnesium sulfate compared with placebo or standard ventilator management alone, sildenafil infusion, adenosine infusion, or inhaled nitric oxide on mortality or the use of backup iNO or ECMO

Cochrane2007

85. Intravenous magnesium for acute myocardial infarction.

Intravenous magnesium for acute myocardial infarction. BACKGROUND: Mortality and morbidity from acute myocardial infarction (AMI) remain high. Intravenous magnesium started early after the onset of AMI is thought to be a promising adjuvant treatment. Conflicting results from earlier trials and meta-analyses warrant a systematic review of available evidence. OBJECTIVES: To examine the effect of intravenous magnesium versus placebo on early mortality and morbidity. SEARCH STRATEGY: We searched (...) CENTRAL (The Cochrane Library Issue 3, 2006), MEDLINE (January 1966 to June 2006) and EMBASE (January 1980 to June 2006), and the Chinese Biomedical Disk (CBM disk) (January 1978 to June 2006). Some core Chinese medical journals relevant to the cardiovascular field were hand searched from their starting date to the first-half year of 2006. SELECTION CRITERIA: All randomized controlled trials that compared intravenous magnesium with placebo in the presence or absence of fibrinolytic therapy in addition

Cochrane2007

86. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis

Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis Mohammed S, Goodacre S CRD summary The review assessed the effectiveness of intravenous and nebulised magnesium sulphate in children and adults with acute asthma. It concluded that intravenous magnesium (...) sulphate was effective in improving respiratory function and reducing hospital admissions in children, but the effectiveness of the treatment was uncertain in adults. Due to substantial variation in some analyses, the reliability of these conclusions is unclear. Authors' objectives To assess the effectiveness of intravenous and nebulised magnesium sulphate on hospital admissions and pulmonary function in adults and children with acute asthma Searching The Cochrane Airways Review Group Asthma Register

DARE.2007

87. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis

Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Ho K M, Sheridan D J, Paterson T CRD summary This well-conducted review found that intravenous magnesium is not effective in converting acute onset atrial fibrillation to sinus rhythm in patients with a normal serum magnesium (...) concentration. The addition of intravenous magnesium to digoxin reduces fast ventricular response rates, but is less effective than other calcium antagonists or amiodarone. These findings are likely to be reliable. Authors' objectives To determine the effectiveness of intravenous magnesium in the conversion of acute onset atrial fibrillation (AF) to sinus rhythm, and in reducing ventricular response and risk of bradycardia. Searching The Cochrane CENTRAL Register, EMBASE and MEDLINE were searched to May

DARE.2007

88. ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response

ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Article Text Therapeutics ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2006

90. Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in adults.

Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in adults. BACKGROUND: Previous research suggests that increasing dietary intakes of calcium, potassium or magnesium separately may reduce BP to a small degree over the short term. It is unclear whether increasing intakes of a combination of these minerals produces a larger reduction in BP. OBJECTIVES: To evaluate the effects of combined mineral supplementation as a treatment for primary (...) a combination of potassium, and/or calcium, and/or magnesium with placebo, no treatment, or usual care; 2) treatment and follow-up >=8 weeks; 3) participants over 18 years old, with raised systolic blood pressure (SBP) >=140 mmHg or diastolic blood pressure (DBP) >=85 mmHg with no known primary cause; 4) SBP and DBP reported at end of follow-up. We excluded trials where participants were pregnant, or received antihypertensive medication which changed during the study. DATA COLLECTION AND ANALYSIS

Cochrane2006

91. Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation

Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Article Text Treatment Review: magnesium prophylaxis after cardiac surgery reduces the risk of arrhythmia and atrial fibrillation Free Gina

Evidence-Based Nursing (Requires free registration)2006

92. Intravenous magnesium in shock resistant tachyarrhythmias

Intravenous magnesium in shock resistant tachyarrhythmias BestBets: Intravenous Magnesium in shock-resistant tachyarrhythmias Intravenous Magnesium in shock-resistant tachyarrhythmias Report By: Ayan Sen - Senior House Officer, Anaesthetics and Intensive Care Search checked by Shweta Gidwani - Clinical Effectiveness Fellow Institution: Fairfield Hospital,Bury Date Submitted: 21st December 2005 Date Completed: 1st March 2006 Last Modified: 21st December 2005 Status: Green (complete) Three Part (...) Question Does [intravenous magnesium] lead to [return of spontaneous circulation] in [shock-resistant tachyarrhythmias] Clinical Scenario A 65 year old man suffered a witnessed out-of-hospital cardiac arrest. He received 20 minutes of basic and advances cardiac life support measures in the field. On arrival in the emergency department, the rhythm showed persistent ventricular fibrillation and he continued to be pulseless. You decide to continue another cycle of defibrillation and think of anti

BestBETS2006

93. Nebulized magnesium sulfate in the management of acute exacerbations of asthma

Nebulized magnesium sulfate in the management of acute exacerbations of asthma Nebulized magnesium sulfate in the management of acute exacerbations of asthma Nebulized magnesium sulfate in the management of acute exacerbations of asthma Villeneuve E J, Zed P J CRD summary This review concluded that there was insufficient evidence to determine the role of nebulised magnesium sulphate in the treatment of acute exacerbations of asthma. The review had methodological limitations (limited search (...) and no validity assessment) and only six small studies were included. However, the authors' cautious conclusions, and their recommendation for further research, appear appropriate. Authors' objectives To evaluate the efficacy and safety of nebulised magnesium sulphate (NMS) for treating acute exacerbations of asthma. Searching MEDLINE/PubMed and EMBASE were searched to October 2005; the search terms were reported. The searches were restricted to publications in the English language. Abstracts were excluded

DARE.2006

94. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials

Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials Song Y, He K, Levitan E B, Manson J E, Liu S CRD summary (...) The authors concluded that oral magnesium supplementation for 4 to 16 weeks may reduce plasma glucose levels and increase high-density lipoprotein cholesterol in patients with type 2 diabetes, but the long-term benefits and safety of magnesium treatment are unclear. This was a well-conducted and clearly reported review. The authors’ cautious conclusions reflect the evidence and are likely to be reliable. Authors' objectives To evaluate the effects of supplementation with oral magnesium on glycaemic

DARE.2006

95. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial

Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial Simon J, Gray A, Duley L, Magpie Trial Collaborative Group (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The present study compared the use of magnesium sulphate (MgSO4) in women with pre-eclampsia with no such prophylaxis (placebo), within the context of the Magnesium Sulphate

NHS Economic Evaluation Database.2006

96. The Magic of Magnesium as an Adjunct in Atrial Fibrillation

The Magic of Magnesium as an Adjunct in Atrial Fibrillation The Magic of Magnesium as an Adjunct in Atrial Fibrillation « Sinai EM Journal Club Emergency Medicine Discussion Forum The Magic of Magnesium as an Adjunct in Atrial Fibrillation Dinali did a stellar job this month at Journal Club; not only was her talk thought-provoking and clinically relevant, but I learned more about the history of of than I would have ever thought possible. This month’s JC was primarily about Davey and Teubner’s (...) AEM paper on using Magnesium sulfate as an adjunct to “usual care” for rate control in atrial fibrillation ( ). We also touched upon some data from an all-Greek study in the Int’l Journal of Cardiology on Mg alone vs diltiazem alone in A-fib ( ). Davey and Taubner looked at 199 Australians with rapid afib in this prospective, randomized, double-blinded, placebo-controlled trial. They got “standard rate-reduction agents” plus placebo, or te same agents plus 20 mEq of magnesium sulfate infused over

Sinai EM Journal Club2006

97. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial.

Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. 17055945 2006 10 23 2006 11 02 2015 06 16 1474-547X 368 9545 2006 Oct 21 Lancet (London, England) Lancet Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. 1436-43 The most common cause of death in individuals with severe tetanus in the absence of mechanical ventilation is spasm-related respiratory failure, whereas in ventilated patients it is tetanus-associated autonomic (...) dysfunction. Our aim was to determine whether continuous magnesium sulphate infusion reduces the need for mechanical ventilation and improves control of muscle spasms and autonomic instability. We did a randomised, double blind, placebo controlled trial in 256 Vietnamese patients over age 15 years with severe tetanus admitted to the Hospital for Tropical Medicine, Ho Chi Minh City, Vietnam. Participants were randomly assigned magnesium sulphate (n=97) or placebo solution (n=98) intravenously for 7 days

Lancet2006

98. Combined vitamin B6-magnesium treatment in autism spectrum disorder.

Combined vitamin B6-magnesium treatment in autism spectrum disorder. BACKGROUND: The use of mega-vitamin intervention began in the 1950s with the treatment of schizophrenic patients. Pyroxidine (vitamin B6) was first used with children diagnosed with "autism syndrome" when speech and language improvement was observed in some children as a result of large doses of B6. A number of studies attempted to assess the effects of vitamin B6-Magnesium (Mg) was found to reduce undesirable side effects (...) from B6) on characteristics such as verbal communication, non-verbal communication, interpersonal skills, and physiological function, in individuals with autism. OBJECTIVES: To determine the efficacy of vitamin B6 and magnesium (B6-Mg) for treating social, communication, and behavioural responses of children and adults with autism. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register (Cochrane Library, Issue 2, 2002), MEDLINE (1966 to January 2002), EMBASE (1980 to January 2002

Cochrane2005

99. Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery?

Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery? BestBets: Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery? Does magnesium offer any additional benefit in patients having anti-arrhythmic treatment for atrial fibrillation following cardiac surgery? Report By: Anish Patel, Jagan Rao - Cardiothoracic Registrars Search (...) checked by J Desmond - Cardiothoracic Registrar RCS Institution: Department of Cardiothoracic Surgery, Freeman Hospital, Freeman Road, Newcastle-upon-Tyne Date Submitted: 15th April 2003 Date Completed: 29th July 2005 Last Modified: 6th May 2003 Status: Green (complete) Three Part Question In [patients undergoing cardiac surgery, going into atrial fibrillation] is [the addition of magnesium] more effective than standard therapy alone in [cardioverting or controlling ventricular rate]. Clinical

BestBETS2005

100. Magnesium intake in relation to risk of colorectal cancer in women.

Magnesium intake in relation to risk of colorectal cancer in women. CONTEXT: Animal studies have suggested that dietary magnesium may play a role in the prevention of colorectal cancer, but data in humans are lacking. OBJECTIVE: To evaluate the hypothesis that a high magnesium intake reduces the risk of colorectal cancer in women. DESIGN, SETTING, AND PARTICIPANTS: The Swedish Mammography Cohort, a population-based prospective cohort of 61,433 women aged 40 to 75 years without previous (...) diagnosis of cancer at baseline from 1987 to 1990. MAIN OUTCOME MEASURE: Incident invasive colorectal cancer. RESULTS: During a mean of 14.8 years (911 042 person-years) of follow-up, 805 incident colorectal cancer cases were diagnosed. After adjustment for potential confounders, we observed an inverse association of magnesium intake with the risk of colorectal cancer (P for trend = .006). Compared with women in the lowest quintile of magnesium intake, the multivariate rate ratio (RR) was 0.59 (95

JAMA2005